SaNOtize Research & Development




8755 Ash street Vancouver, BC V6P 6T3


Member Sector: Biopharmaceuticals

SaNOtize has developed a proprietary method to effectively deliver nitric oxide to the site of an infection.  Nitric oxide (NO) has been shown to be effective as an antiviral, antibacterial, antifungal, and also enhances wound healing. The historical challenge has been how to deliver NO effectively since it is a gas molecule.  The company has successfully solved the delivery issue, and now has a true platform technology for upper respiratory and topical dermal infections. 


SaNOtize has developed products for chronic sinusitis, diabetic foot ulcers and onychomycosis, two of which are in the clinical trials. Phase II clinical trials to use their nasal spray against the COVID-19 virus are also on-going at sites across Canada.  So far, treatment data looks very compelling.  SaNOtize’s formulation inactivated more than 99.9% of the SARS-CoV-2 virus within two minutes in the laboratory setting.